- |||||||||| fencamfamine prodrug (PRX-P4-003) / Praxis Bioresearch
Enrollment closed, Trial primary completion date: Microdose Pharmacokinetic Study of PRX-P4-003 In Healthy Volunteers (clinicaltrials.gov) - Sep 16, 2021
P1, N=8, Active, not recruiting,
Active, not recruiting --> Completed Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2021 --> Oct 2021
- |||||||||| fencamfamine prodrug (PRX-P4-003) / Praxis Bioresearch
[VIRTUAL] Microdose Study of a Novel Psychostimulant Prodrug, PRX-P4-003, with Reduced Abuse Liability for Apathy in AD () - Aug 7, 2021 - Abstract #CTAD2021CTAD_230;
The finding of a much earlier peak concentration in the fed state is consistent with the postulated dependence of release of pancreatic lipases into the gut following ingestion of food. The properties of PRX-P4-003 shown in this microdose study support its further development for the treatment of apathy in AD as a drug with at least equivalent efficacy to methylphenidate and a lower liability of abuse or diversion.
- |||||||||| fencamfamine prodrug (PRX-P4-003) / Praxis Bioresearch
Trial completion date: Microdose Pharmacokinetic Study of PRX-P4-003 In Healthy Volunteers (clinicaltrials.gov) - May 17, 2021
P1, N=8, Recruiting,
The properties of PRX-P4-003 shown in this microdose study support its further development for the treatment of apathy in AD as a drug with at least equivalent efficacy to methylphenidate and a lower liability of abuse or diversion. Trial completion date: Jun 2021 --> Oct 2021
|
